Digestive Health Newsletter

Take Steps Toward Colorectal Cancer Prevention

Carol A. Burke, MD, FACG, FACP

Volume 25, 
March 01, 2011

by Carol A. Burke, MD, FACG, FACP

Carol Burke Carol A. Burke, MD, FACG, FACP, is a staff member in the Department of Gastroenterology and Hepatology at the Cleveland Clinic in Cleveland, Ohio, and holds a joint appointment in the Taussig Cancer Center and Department of Colorectal Surgery. She also serves as Director of the Center for Colon Polyp and Cancer Prevention and Head of the David G. Jagelman Inherited Colon Cancer Polyposis Registry at the Cleveland Clinic. Dr. Burke is internationally known for her expertise in the prevention of colorectal neoplasia and in inherited colon cancer syndromes. She has authored or coauthored more than 50 publications and serves as an associate editor of the American Journal of Gastroenterology as well as a reviewer for many journals, including Gastroenterology and Gastrointestinal Endoscopy.


Table of Contents



Introduction

March is National Colorectal Cancer Awareness month -- a good time to reflect on the fact that, although inflammatory bowel disease (IBD) increases your colorectal cancer risk by about two to five times the average, colorectal cancer is largely preventable and one of the most treatable cancers if detected early. The most important step you can take is to follow your doctor’s recommendations regarding surveillance colonoscopy. For example, if you’ve had IBD for eight to ten years, your doctor will probably recommend that you schedule a colonoscopy every one to two years. This newsletter focuses on some of the additional steps you can take toward general colorectal cancer prevention and good health.

Back to Top

Choose alternative sources of protein (fish, poultry, legumes, soy, low-fat dairy) instead of red meat.

Researchers have found that both red meat and processed meat consumption increases colorectal cancer risk. For example, a European study followed 478,000 men and women who were cancer-free when the study began. By the end of the study, the people who ate the most red meat (at least 5 ounces per day) were about 30% more likely to develop colon cancer than were those who ate an average of less than an ounce of red meat each day. Grilling meats at high-temperatures for prolonged periods of time may increase risk even further. So if you eat red meat, do so in moderation and keep portions small. And if you like to grill occasionally, partially precook the meat first and then grill at low temperatures.

Back to Top

Get enough calcium.

Calcium is important for more than strong bones. In fact, scientific research consistently shows a significant, inverse relationship between calcium intake and colorectal cancer risk. Although this relationship has not been studied specifically in people with IBD, it makes sense to make sure you are getting enough calcium. Good sources of calcium are low-fat yogurt, part-skim mozzarella cheese, skim milk, and sardines. See the table below for information about how much vitamin D you need each day.

Back to Top

Get enough vitamin D.

A number of recent studies suggest that vitamin D deficiency may increase colon cancer risk. While researchers are still working to determine optimal blood levels and dietary intake recommendations, it is evident that many people in the U.S. are not getting enough of this key nutrient.

It can be difficult to meet your vitamin D needs through the foods you eat, since the best dietary sources are limited to fatty fish (e.g., salmon, tuna, and mackerel) or foods that are fortified with vitamin D (for example, milk, as well as some brands of breakfast cereals, orange juice, yogurt, margarine, and soy beverages). Smaller amounts can be found in beef liver, cheese, egg yolk, and mushrooms. Your body also makes vitamin D when your skin is exposed to the sun. But keep in mind that, when you’re inside, the sunlight reaching your skin through a window isn’t strong enough to make vitamin D. Also, if you live in the northern half of the United States, the sun isn’t strong enough for your skin to make vitamin D in the winter. See the table below for information about how much vitamin D you need each day.

When you have IBD, it may be difficult to get enough vitamin D. Checking your levels is as easy as contacting your healthcare provider for a blood test. The normal range is currently estimated to be between 30 and 74 ng/mL.

Back to Top

Get enough folic acid.

Although the relationship between folic acid (a B vitamin) and colorectal cancer is less clear than the relationship between calcium and colorectal cancer, it makes sense to make sure you are meeting your folic acid needs – 400 μg/day for adults. Good sources of folic acid are leafy green vegetables (like spinach and kale), citrus fruits, and dried beans and peas. Folic acid is also added to all enriched breads, cereals, flours, corn meals, pasta, rice, and other grain products.

Back to Top

Minimize alcohol intake.

Most research suggests that a high intake of alcohol increases colorectal cancer risk. For example, an analysis of more than 100 studies focusing on colorectal cancer risk factors found that, when compared with adults who were light drinkers or non-drinkers, those who averaged a drink per day or more had a 60% higher risk of colorectal cancer.

Back to Top

If you smoke, quit.

Tobacco use has been consistently associated with increased colorectal cancer risk, with approximately 15% to 20% of colorectal cancers attributed to smoking. Even though nicotine has been linked to a decreased risk of developing ulcerative colitis, as well as to decreased symptoms if you already have ulcerative colitis, smoking-related risks far outweigh any benefit. If you smoke, talk to your doctor about strategies to quit, or check out the resources on the Centers for Disease Control and Prevention’s Web site.

Back to Top

Maintain a healthy body weight.

Excess body weight has been linked to many diseases, and colorectal cancer is one of them, especially when the weight is concentrated around your middle. To lose weight, you must burn more calories than you consume. Slow and steady is the key – people who lose just a few pounds each week are most successful at keeping it off.

Since one pound of fat is equal to 3,500 calories, you need to reduce your intake by 500 to 1,000 calories each day lose about one to two pounds per week. Instead of fad diets or programs that you will tire of, focus on lifestyle changes that you can maintain.

If you are already at a healthy body weight and want to prevent weight gain, focus on good eating habits and regular physical activity. Remember that, as you age, your body composition will shift to less muscle and more fat, which can slow your metabolism and lead to weight gain. For more information, check out the Center for Disease Control and Prevention’s tips for losing weight or maintaining weight, or the American College of Gastroenterology’s webpage about obesity.

Back to Top

Make physical activity part of your week.

People with increased levels of physical activity appear to have a decreased risk of colorectal cancer. For example, a review of 52 studies indicated that physically active individuals had 20% to 30% lower risk of colon cancer when compared to their less active peers. Even moderate levels of physical activity – like brisk walking for three to four hours per week – are associated with substantial decreases in risk.

Back to Top

Take your medication.

Scientists think that long-term suppression of inflammation may stop normal cells from becoming precancerous or cancerous. Therefore, taking your IBD medication regularly, even when you are feeling well, may reduce your colorectal cancer risk. Aminosalicylates (5-ASA drugs like mesalamine, balsalazide, sulfasalzine, and olsalazine), in particular, seem to have a positive effect on risk. For example, a Mayo Clinic study found a 60% decrease in colorectal cancer risk for patients with ulcerative colitis who took mesalamine for 1 to 5 years, compared to patients who took mesalamine for less than 1 year.

If you have both ulcerative colitis and primary sclerosing cholangitis (PSC), you are at especially high risk for colorectal cancer. But the good news is that ursodeoxycholic acid (URSO), which is used to treat PSC, may decrease your risk. More research is needed to determine if URSO decreases colorectal cancer risk in IBD patients who do not have PSC.

Back to Top

Conclusion

While colorectal cancer is a serious concern, especially if you have IBD, you needn’t feel powerless. Remember that your most powerful prevention tool is a colonoscopy, so be sure to follow your healthcare provider’s screening recommendations. Then, focus on the lifestyle changes you can make to reduce your risk even further.

Back to Top


 
Dietary Recommendations for Calcium, Males and Females*
Age group Dietary Recommendations (mg**/day)
0-6 months 210 mg
7-12 months 270 mg
1-3 years 500 mg
4-8 years 800 mg
9-18 years 1300 mg
19-50 years 1000 mg
51 years and older 1200 mg

* Institute of Medicine, Food and Nutrition Board. Dietary Reference


Intakes for Calcium and Vitamin D. Washington, DC: National Academy

Press, 2010.

(http://www.iom.edu/~/media/Files/Report%20Files/2010/Dietary-

Reference-Intakes-for-Calcium-and-Vitamin-

D/Vitamin%20D%20and%20Calcium%202010%20Report%20Brief.pdf)


**mg = milligram

Dietary Recommendations for Vitamin D, Males and Females*
Age group Dietary Recommendations (IU**/day)
Birth to 12 months 400 IU
Children 1–13 years 600 IU
Teens 14–18 years 600 IU
Adults 19–70 years 600 IU
Adults 71 years and older 800 IU
Pregnant and breastfeeding teens and women 600 IU

* Institute of Medicine, Food and Nutrition Board. Dietary

Reference Intakes for Calcium and Vitamin D. Washington, DC:

National Academy Press, 2010.

(http://www.iom.edu/~/media/Files/Report%20Files/2010/Dietary-

Reference-Intakes-for-Calcium-and-Vitamin-

D/Vitamin%20D%20and%20Calcium%202010%20Report%20Brief.pdf)


**IU = International Unit

Important Safety Information about AZASAN

WARNING: Chronic immunosuppression with this purine antimetabolite increases risk of neoplasia in humans. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. See WARNINGS section in complete Prescribing Information.

AZASAN® (azathioprine tablets) 75/100 mg is indicated as an adjunct for the prevention of rejection in renal homotransplantations, and also for the management of active rheumatoid arthritis to reduce signs and symptoms.The most commonly reported side effects associated with AZASAN therapy are leukopenia and/or thrombocytopenia, secondary infections, neoplasia, nausea, vomiting, diarrhea, fever, myalgias, skin rashes, and hepatotoxicity. AZASAN therapy should be given cautiously when used concomitantly with allopurinol, ACE inhibitors, and other agents affecting myelopoiesis. AZASAN is contraindicated in pregnant and lactating women and in patients who have shown hypersensitivity to this product.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for AZASAN, including BOXED WARNINGpdf

Important Safety Information about METOZOLV® ODT

WARNING: TARDIVE DYSKINESIA

See full prescribing information for complete boxed warning.

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.

Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.

Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

METOZOLV® ODT (metoclopramide HCl) is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric stasis) in adults. Therapy should not exceed 12 weeks in duration. Take on an empty stomach up to four times daily, at least 30 minutes before eating and at bedtime.

METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage, or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal reactions.

Extrapyramidal symptoms (EPS), manifested primarily as acute dystonic reactions, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age and are even more frequent at higher doses.

Drug-induced Parkinsonism can occur during metoclopramide therapy, more commonly within the first 6 months after beginning treatment, but also after longer periods. Patients with a history of Parkinson’s disease should be given metoclopramide cautiously, if at all, since such patients can experience exacerbation of Parkinsonian symptoms when taking metoclopramide.

There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) associated with metoclopramide. Clinical manifestations of NMS include hyperthermia, muscle rigidity, altered consciousness, and evidence of autonomic instability. The management of NMS should include immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy.

Depression associated with metoclopramide use has occurred in patients with and without a history of depression. For those patients with a prior history of depression, metoclopramide should only be given if the expected benefits outweigh the potential risks.

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, caution should be exercised when metoclopramide is used in patients with hypertension. Any rapid rise in blood pressure associated with METOZOLV ODT use should result in immediate cessation of metoclopramide use in those patients.

Since metoclopramide produces a transient increase in plasma aldosterone, patients with cirrhosis or congestive heart failure may be at risk of developing fluid retention and volume overload. If these side effects occur at any time in any patients during metoclopramide therapy, the drug should be discontinued.

Adverse reactions, especially those involving the nervous system, may occur after stopping the use of METOZOLV ODT.

In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.

Complete Prescribing Information for METOZOLV ODT, including BOXED WARNING pdf

Important Safety Information about OSMOPREP

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long–term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti–inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OSMOPREP is used in patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, severe chronic constipation, bowel perforation, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal function, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OSMOPREP.

OSMOPREP is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients, and in patients with biopsy–proven acute phosphate nephropathy. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OSMOPREP be advised to adequately hydrate before, during, and after the use of OsmoPrep.

For complete Prescribing Information for OSMOPREP including BOXED WARNING.pdf

Important Safety Information about VISICOL

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long-term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

VISICOL® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. VISICOL is not to be used in patients with congestive heart failure, ascites, unstable angina pectoris, gastric retention, ileus or acute obstruction or pseudo-obstruction, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, or hypomotility syndrome. Use with caution in patients with impaired renal function, pre-existing electrolyte disturbances, or people taking drugs that affect electrolyte levels. VISICOL is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. In clinical trials, the most commonly observed (≥1%) adverse reactions occurring with use of VISICOL were generally transient and self-limited and included nausea, vomiting, abdominal bloating, abdominal pain, dizziness and headache.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for VISICOL, including BOXED WARNING pdf

The information contained on this page is intended for US patients, healthcare professionals, and pharmacists only.

SWB 11/01

Salix Pharmaceuticals on Facebook   Salix Pharmaceuticals on Twitter